SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D

It has been demonstrated that certain NK-1 antagonists could reduce proliferation of several cancer cell lines, however, it is unknown whether SR140333 exerts proliferation inhibition in breast cancer cell line. Immunohistochemical staining was carried out to investigate the immunolocation of NK-1 i...

Full description

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 29; no. 1; p. 55
Main Authors Huang, Wei-Qing, Wang, Ji-Gang, Chen, Lei, Wei, Hong-Jun, Chen, Hua
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 24.05.2010
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:It has been demonstrated that certain NK-1 antagonists could reduce proliferation of several cancer cell lines, however, it is unknown whether SR140333 exerts proliferation inhibition in breast cancer cell line. Immunohistochemical staining was carried out to investigate the immunolocation of NK-1 in breast cancer tissues and T47D cell line, thereafter, various concentrations of [Sar9, Met(O2)11]substance P and SR140333 were applied alone or combined. MTT assay was applied to detect cytoactivation and coulter counter was to detect growth curve. The Hoechst33258 staining was performed to detect apoptosis. We found that breast cancer and T47D cells bear positive expression of NK-1. SR140333 inhibited cell growth in a dose dependent manner. Furthermore, SR140333 could counteract [Sar9, Met(O2)11]substance P induced proliferation. Hoechst33258 staining revealed the presence of apoptosis after SR140333 treatment. Our study demonstrated SR140333 exert proliferation inhibition in breast cancer cell line T47D and indicates NK-1 play a central role in the substance P related cell proliferation in breast cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1756-9966
0392-9078
1756-9966
DOI:10.1186/1756-9966-29-55